Sheba Medical Center
Ramat Gan, Israel
78 recruiting
Showing 1–20 of 165 trials
Recruiting
Phase 3
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Crohn Disease
Janssen Research & Development, LLC460 enrolled55 locationsNCT07577843
Recruiting
Phase 3
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Colorectal Neoplasms
Janssen Research & Development, LLC700 enrolled250 locationsNCT06750094
Recruiting
Phase 3
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
Colitis Ulcerative
Janssen Research & Development, LLC644 enrolled63 locationsNCT07577856
Recruiting
Phase 2
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC480 enrolled203 locationsNCT06667076
Recruiting
Phase 1
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
MelanomaNon-small Cell Lung CancerThyroid Cancer+2 more
Pfizer267 enrolled40 locationsNCT05355701
Recruiting
Phase 1
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC240 enrolled16 locationsNCT06768489
Recruiting
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Relapsed Refractory Multiple Myeloma (RRMM)
Janssen-Cilag Ltd.900 enrolled68 locationsNCT06285318
Recruiting
Phase 3
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC220 enrolled112 locationsNCT06919965
Recruiting
Phase 3
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC400 enrolled124 locationsNCT07258511
Recruiting
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC380 enrolled80 locationsNCT07230691
Recruiting
Phase 3
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Colorectal Neoplasms
Janssen Research & Development, LLC1,000 enrolled238 locationsNCT06662786
Recruiting
Phase 1
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Neoplasms
Janssen Research & Development, LLC241 enrolled39 locationsNCT06150157
Recruiting
Phase 3
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Colitis Ulcerative
Janssen Research & Development, LLC882 enrolled400 locationsNCT07196748
Recruiting
Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer492 enrolled270 locationsNCT06152575
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Acute Leukemia
Janssen Research & Development, LLC420 enrolled102 locationsNCT04811560
Recruiting
Phase 3
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC700 enrolled88 locationsNCT07518186
Recruiting
Phase 1Phase 2
Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome
Pitt Hopkins Syndrome
Mahzi Therapeutics12 enrolled4 locationsNCT07135050
Recruiting
Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled175 locationsNCT01804686
Recruiting
Phase 3
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Prostate CancerCancer of the ProstateHormone Sensitive Prostate Cancer+1 more
Pfizer1,000 enrolled341 locationsNCT07028853
Recruiting
Phase 1Phase 2
Safety of HRX215 in Patients After Minor and Major Liver Resection
Liver ResectionColorectal Carcinoma Liver Metastases
HepaRegeniX GmbH80 enrolled12 locationsNCT06638502